The Treatment of Severe Staphylococcal Infections with Vancomycin
- 1 August 1961
- journal article
- research article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 55 (2) , 235-249
- https://doi.org/10.7326/0003-4819-55-2-235
Abstract
The efficacy of vancomycin (Vancocin®—Lilly) in the treatment of severe staphylococcal infections is becoming well established. According to several authors it is now the agent of choice if the organism is penicillin-resistant (1-3). Vancomycin has a bactericidal action for staphylococci, and as yet no resistant strains have been reported in clinical practice. Toxicity is often bothersome, but it is rarely serious or a cause for discontinuing therapy. A summary of our experience with this drug in 25 cases of serious staphylococcal infections will be presented, along with a review of the literature on vancomycin. The following cases are reported inKeywords
This publication has 4 references indexed in Scilit:
- Treatment of Staphylococcal Septicemia with VancomycinNew England Journal of Medicine, 1960
- VANCOMYCIN IN THE TREATMENT OF STAPHYLOCOCCAL ENDOCARDITIS1960
- RATE OF DEVELOPMENT OF RESISTANCE IN STAPHYLOCOCCUS-AUREUS TO ERYTHROMYCIN IN COMBINATION WITH OLEANDOMYCIN, VANCOMYCIN, OR DIHYDROSTREPTOMYCIN1960
- ANTIBIOTIC THERAPY OF BACTERIAL ENDOCARDITIS .7. VANCOMYCIN FOR ACUTE MICROCOCCAL ENDOCARDITIS - PRELIMINARY REPORT1958